Cutting-edge CAR engineering: beyond T cells

Chimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks efficacy in solid tumours, possibly because engineered T cells become inactive with...

Descripción completa

Detalles Bibliográficos
Autores: Chocarro de Erauso, Luisa, Blanco, Ester, Fernández Rubio, Leticia, Arasanz Esteban, Hugo, Bocanegra Gondán, Ana Isabel, Echaide Górriz, Míriam, Garnica, Maider, Ramos, Pablo, Piñeiro Hermida, Sergio, Vera García, Ruth, Kochan, Grazyna, Escors Murugarren, David
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad Pública de Navarra
Repositorio:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
OAI Identifier:oai:academica-e.unavarra.es:2454/45147
Acceso en línea:https://hdl.handle.net/2454/45147
Access Level:acceso abierto
Palabra clave:CAR-macrophage
CAR-monocyte
CAR-myeloid
CAR-NK
Immunotherapy
Tumour microenvironment
id ES_2e994d5cccc9db0c28f293342e13fe4e
oai_identifier_str oai:academica-e.unavarra.es:2454/45147
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cutting-edge CAR engineering: beyond T cellsChocarro de Erauso, LuisaBlanco, EsterFernández Rubio, LeticiaArasanz Esteban, HugoBocanegra Gondán, Ana IsabelEchaide Górriz, MíriamGarnica, MaiderRamos, PabloPiñeiro Hermida, SergioVera García, RuthKochan, GrazynaEscors Murugarren, DavidCAR-macrophageCAR-monocyteCAR-myeloidCAR-NKImmunotherapyTumour microenvironmentChimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks efficacy in solid tumours, possibly because engineered T cells become inactive within the immunosuppressive tumour microenvironment (TME). In the TME, cells of the myeloid lineage (M) are among the immunosuppressive cell types with the highest tumour infiltration rate. These cells interact with other immune cells, mediating immunosuppression and promoting angiogenesis. Recently, the development of CAR-M cell therapies has been put forward as a new candidate immunotherapy with good efficacy potential. This alternative CAR strategy may increase the efficacy, survival, persistence, and safety of CAR treatments in solid tumours. This remains a critical frontier in cancer research and opens up a new possibility for next-generation personalised medicine to overcome TME resistance. However, the exact mechanisms of action of CAR-M and their effect on the TME remain poorly understood. Here, we summarise the basic, translational, and clinical results of CAR-innate immune cells and CAR-M cell immunotherapies, from their engineering and mechanistic studies to preclinical and clinical development.The OncoImmunology group is funded by the Spanish Association against Cancer (AECC) [grant number PROYE16001ESCO]; Instituto de Salud Carlos III (ISCIII)-FEDER project grants [grant numbers FIS PI17/02119, FIS PI20/00010, COV20/00000, TRANSPOCART ICI19/00069]; a Biomedicine Project grant from the Department of Health of the Government of Navarre [grant number BMED 050-2019]; strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); European Project Horizon 2020 Improved Vaccination for Older Adults (ISOLDA; ID: 848166); Crescendo Biologics Ltd. supported the OncoImmunology group for the development and testing of PD-1 and LAG-3 bispecifics.MDPICiencias de la SaludOsasun Zientziak2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/ziphttps://hdl.handle.net/2454/45147reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarrainstname:Universidad Pública de NavarraInglésinfo:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000013info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000033info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2019-000058© 2022 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:academica-e.unavarra.es:2454/451472026-06-17T12:41:47Z
dc.title.none.fl_str_mv Cutting-edge CAR engineering: beyond T cells
title Cutting-edge CAR engineering: beyond T cells
spellingShingle Cutting-edge CAR engineering: beyond T cells
Chocarro de Erauso, Luisa
CAR-macrophage
CAR-monocyte
CAR-myeloid
CAR-NK
Immunotherapy
Tumour microenvironment
title_short Cutting-edge CAR engineering: beyond T cells
title_full Cutting-edge CAR engineering: beyond T cells
title_fullStr Cutting-edge CAR engineering: beyond T cells
title_full_unstemmed Cutting-edge CAR engineering: beyond T cells
title_sort Cutting-edge CAR engineering: beyond T cells
dc.creator.none.fl_str_mv Chocarro de Erauso, Luisa
Blanco, Ester
Fernández Rubio, Leticia
Arasanz Esteban, Hugo
Bocanegra Gondán, Ana Isabel
Echaide Górriz, Míriam
Garnica, Maider
Ramos, Pablo
Piñeiro Hermida, Sergio
Vera García, Ruth
Kochan, Grazyna
Escors Murugarren, David
author Chocarro de Erauso, Luisa
author_facet Chocarro de Erauso, Luisa
Blanco, Ester
Fernández Rubio, Leticia
Arasanz Esteban, Hugo
Bocanegra Gondán, Ana Isabel
Echaide Górriz, Míriam
Garnica, Maider
Ramos, Pablo
Piñeiro Hermida, Sergio
Vera García, Ruth
Kochan, Grazyna
Escors Murugarren, David
author_role author
author2 Blanco, Ester
Fernández Rubio, Leticia
Arasanz Esteban, Hugo
Bocanegra Gondán, Ana Isabel
Echaide Górriz, Míriam
Garnica, Maider
Ramos, Pablo
Piñeiro Hermida, Sergio
Vera García, Ruth
Kochan, Grazyna
Escors Murugarren, David
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ciencias de la Salud
Osasun Zientziak
dc.subject.none.fl_str_mv CAR-macrophage
CAR-monocyte
CAR-myeloid
CAR-NK
Immunotherapy
Tumour microenvironment
topic CAR-macrophage
CAR-monocyte
CAR-myeloid
CAR-NK
Immunotherapy
Tumour microenvironment
description Chimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks efficacy in solid tumours, possibly because engineered T cells become inactive within the immunosuppressive tumour microenvironment (TME). In the TME, cells of the myeloid lineage (M) are among the immunosuppressive cell types with the highest tumour infiltration rate. These cells interact with other immune cells, mediating immunosuppression and promoting angiogenesis. Recently, the development of CAR-M cell therapies has been put forward as a new candidate immunotherapy with good efficacy potential. This alternative CAR strategy may increase the efficacy, survival, persistence, and safety of CAR treatments in solid tumours. This remains a critical frontier in cancer research and opens up a new possibility for next-generation personalised medicine to overcome TME resistance. However, the exact mechanisms of action of CAR-M and their effect on the TME remain poorly understood. Here, we summarise the basic, translational, and clinical results of CAR-innate immune cells and CAR-M cell immunotherapies, from their engineering and mechanistic studies to preclinical and clinical development.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2454/45147
url https://hdl.handle.net/2454/45147
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069
info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000013
info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000033
info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2019-000058
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/zip
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
instname:Universidad Pública de Navarra
instname_str Universidad Pública de Navarra
reponame_str Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
collection Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405415603699712
score 15.811543

Similares en LA Referencia